BI's Mobic NDA May Test Limits Of FDA COX-2 Class Definition
Boehringer Ingelheim's NDA for the nonsteroidal anti-inflammatory drug Mobic (meloxicam) may test the limits of FDA's definition of COX-2 inhibitors and their status as a separate class.
You may also be interested in...
Merck is looking to move patients out of the over-the-counter analgesic market to the prescription COX-2 inhibitor Vioxx, Merck Human Health-The Americas President David Anstice said at Merck's annual business briefing Dec. 9 in Whitehouse Station, N.J.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011